CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRMD CorMedix Inc.

Trading 10-29 15:46:48 EDT

7.59

-0.61

-7.50%

High8.35	Low7.46	Vol1.44M
Open8.34	D1 Closing8.20	Amplitude10.97%
Mkt Cap591.21M	Tradable Cap500.79M	Total Shares77.94M
T/O11.21M	T/O Rate2.18%	Tradable Shares66.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRMD","market":"US","secType":"STK","nameCN":"CorMedix Inc.","latestPrice":7.585,"timestamp":1793303208407,"preClose":8.2,"halted":0,"volume":1438021,"delay":0,"changeRate":-0.07499999999999993,"floatShares":66024300,"shares":77944324,"eps":2.083064,"marketStatus":"Trading","change":-0.615,"latestTime":"10-29 15:46:48 EDT","open":8.34,"high":8.3545,"low":7.455,"amount":11213845.2212995,"amplitude":0.109695,"askPrice":7.59,"askSize":560,"bidPrice":7.58,"bidSize":294,"shortable":3,"etf":0,"ttmEps":2.083064,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793304000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1273723200000,"exchange":"NASDAQ","adjPreClose":8.2,"preHourTrading":{"tag":"盘前","latestPrice":8.33,"preClose":8.2,"latestTime":"09:29 EDT","volume":919,"amount":7610.411772,"timestamp":1793280599995,"change":0.13,"changeRate":0.015854,"amplitude":0.04878},"postHourTrading":{"tag":"盘后","latestPrice":8.135,"preClose":8.2,"latestTime":"19:54 EDT","volume":32405,"amount":265533.561044,"timestamp":1793231648136,"change":-0.065,"changeRate":-0.007927,"amplitude":0.010366},"volumeRatio":1.409274,"impliedVol":0.7411,"impliedVolPercentile":0.6653},"requestUrl":"/m/hq/s/CRMD","defaultTab":"news","newsList":[{"id":"2676680009","title":"CorMedix Price Target Maintained with a $15.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2676680009","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676680009?lang=en_us&edition=fundamental","pubTime":"2026-10-20 01:25","pubTimestamp":1792430700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRMD/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676686872","title":"FDA Grants Priority Review to CorMedix's Rezzayo for Fungal Disease Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2676686872","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676686872?lang=en_us&edition=fundamental","pubTime":"2026-10-19 20:39","pubTimestamp":1792413565,"startTime":"0","endTime":"0","summary":"FDA grants priority review to CorMedix's Rezzayo for fungal disease preventionFDA granted priority review to CorMedix's application for Rezzayo to prevent invasive fungal disease, with a decision targ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nNDL3Q7RSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676887606","title":"CorMedix - Targets Promotional Launch for Rezzayo in H2 2027 if Approved","url":"https://stock-news.laohu8.com/highlight/detail?id=2676887606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676887606?lang=en_us&edition=fundamental","pubTime":"2026-10-19 19:30","pubTimestamp":1792409400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nTUA9PJVDX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676688765","title":"CorMedix Announces FDA Acceptance for Priority Review of Supplemental Nda for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2676688765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676688765?lang=en_us&edition=fundamental","pubTime":"2026-10-19 19:30","pubTimestamp":1792409400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nTUA9PJVDX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676688755","title":"CorMedix - FDA Grants Priority Review for Rezzayo with Pdufa Target Action Date in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2676688755","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676688755?lang=en_us&edition=fundamental","pubTime":"2026-10-19 19:30","pubTimestamp":1792409400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nTUA9PJVDX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675589769","title":"Actinium Pharmaceuticals - Appoints Matt David as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2675589769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675589769?lang=en_us&edition=fundamental","pubTime":"2026-10-15 19:30","pubTimestamp":1792063803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261015:nTUA3ZC4PC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATNM","BK4139","CRMD","BK4007","OVID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669210704","title":"CorMedix Price Target Announced at $15.00/Share by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2669210704","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669210704?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:42","pubTimestamp":1790160120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRMD/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669107786","title":"Oppenheimer Initiates CorMedix at Outperform With $15 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2669107786","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669107786?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:38","pubTimestamp":1790159912,"startTime":"0","endTime":"0","summary":"CorMedix (CRMD) has an average rating of buy and mean price target of $15.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669105916","title":"US Research Roundup- Allstate, Autozone, Vertex Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2669105916","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669105916?lang=en_us&edition=fundamental","pubTime":"2026-09-23 15:36","pubTimestamp":1790149013,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP- Allstate, Autozone, Vertex PharmaceuticalsSept 23 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Allst","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL4N45F0GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYH","BSVN","ALL","CMI","EXI","AMGN","BLCK","ACHC","CWVX","HBAN","PKB","SHLD","APLD","NATO","COLL","ALLY","STZ","CLDX","CMPX","CCL","FITB","BDC","DFEN","GPK","FOXA","ANIX","HUT","AMRX","CBZ","CRWV","WFRD","CIFR","AZO","PBE","GE","CFG","CRWG","CORZ","HUTG","AMRZ","DCH","HCA","AXP","HII","ANAB","CRMD","GRDN","ARDT","GD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659128386","title":"CorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659128386","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659128386?lang=en_us&edition=fundamental","pubTime":"2026-08-14 23:30","pubTimestamp":1786721454,"startTime":"0","endTime":"0","summary":"CorMedix's  last major customer for its DefenCath solution could buoy 2026 volumes and back franchise durability in 2027 and beyond, RBC Capital Markets said in a Thursday note.DefenCath is intended to prevent catheter-related bloodstream infections in patients with end-stage renal disease and the last multi-year contract win with a large dialysis organization in the US indicates continued demand and should boost H2 order volume, RBC said, noting the drug's potential to top $199 million in 2026 revenue.RBC also noted the company's upcoming supplemental new drug application for Rezzayo, which is currently a treatment of candidemia and invasive candidiasis, as a potential growth driver in 2027. Rezzayo's potential label expansion in prophylaxis could unlock a $200 million market opportunity for CorMedix, the brokerage added.RBC raised its price target on CorMedix to $14 from $13, with an outperform rating.Price: 7.75, Change: -0.39, Percent Change: -4.77","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659966149","title":"Annovis Bio Q2 Loss Widens as R&D Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2659966149","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659966149?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:15","pubTimestamp":1786709731,"startTime":"0","endTime":"0","summary":"Annovis Bio Q2 loss widens as R&D costs riseOverviewUS biotech firm's Q2 net loss per share widened yr/yrCompany fully enrolled pivotal Phase 3 Alzheimer's trial, exceeding original targetQ2 research ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0EG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PMN","BK4139","ANVS","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146854","title":"RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146854","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659146854?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:36","pubTimestamp":1786707415,"startTime":"0","endTime":"0","summary":"CorMedix (CRMD) has an average rating of buy and mean price target of $15.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659161058","title":"CorMedix Shares Rise After Q2 Results, Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2659161058","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659161058?lang=en_us&edition=fundamental","pubTime":"2026-08-14 02:41","pubTimestamp":1786646484,"startTime":"0","endTime":"0","summary":"CorMedix  shares were up over 11% in Thursday trading following its Q2 results and guidance.Earlier, the company reported a Q2 earnings of $0.29 per diluted share, up from $0.28 a year earlier.Revenue for the three months ended June 30 was $101.9 million, up from $39.7 million a year earlier.Analysts polled by FactSet expected $97.4 million.For 2026, the company kept its revenue guidance of $325 million to $345 million, while raising its adjusted EBITDA guidance to a range of $125 million to $140 million.Analysts expected $335.3 million for revenue.Price: 7.95, Change: +0.85, Percent Change: +11.90","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659169742","title":"Analysts Are Bullish on Top Healthcare Stocks: Parabilis Medicines, Inc. (PBLS), Cormedix (CRMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659169742","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659169742?lang=en_us&edition=fundamental","pubTime":"2026-08-14 01:30","pubTimestamp":1786642207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Parabilis Medicines, Inc. (PBLS) and Cormedix (CRMD)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-parabilis-medicines-inc-pbls-cormedix-crmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-parabilis-medicines-inc-pbls-cormedix-crmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659119166","title":"U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2659119166","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659119166?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:18","pubTimestamp":1786637899,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-EnerSys, Netflix, SalesforceAugust 13 (Reuters)-The S&P 500 hit an intraday record high on Thursday, boosted by technology stocks, as a drop in crude prices lifted risk ap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL6N44A14N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","DERM","GLNG","RKLB","WQTM","IBM","LWAY","AGMI","CRM","OPEN","CRMD","DIOD","CBRS","BIRK","DELL","DIPR","LESL","TRUM","ARX","LNSR","PYXS","LUNL","RKLX","ENS","ABCL","AKAM","WSPC","CGEM","MH","CSCL","NEM","AVAH","STAA","XLC","NFLX","HLIT","CSCO","FIVE","OTLK","HPQ","DKL","OMER","STUB","TPR","MSGS","SPCE","LUNR","CSCS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659632421","title":"CorMedix Stock Jumps on Strong DefenCath Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2659632421","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659632421?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:56","pubTimestamp":1786632982,"startTime":"0","endTime":"0","summary":"CorMedix Q2 earnings beat estimates as sales more than doubled, DefenCath revenue grew, and the company reaffirmed 2026 sales guidance.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/08/61179766/cormedix-stock-jumps-on-strong-defencath-sales","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SMA","CRMD","BK4217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659150530","title":"CorMedix Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659150530","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659150530?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:31","pubTimestamp":1786627874,"startTime":"0","endTime":"0","summary":"CorMedix Inc. reports results for the quarter ended June 30 - Earnings SummaryCorMedix Inc.CRMD.OQreported quarterly adjusted earnings of 32 cents per share for the quarter ended June 30, higher than ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A1AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659515681","title":"CorMedix Shares Rise 7.1% Premarket After Q2 Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2659515681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659515681?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:46","pubTimestamp":1786621615,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A0J4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659151875","title":"CorMedix Beats Q2 Revenue Estimates on DefenCath Growth, Raises FY Adjusted Ebitda Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2659151875","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659151875?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:42","pubTimestamp":1786621337,"startTime":"0","endTime":"0","summary":"CorMedix beatsQ2 revenue estimates on DefenCath growth, raises FY adjusted EBITDA guidanceOverviewUS biopharma firm's Q2 revenue rose, beating analyst expectationsEPS for Q2 beat analyst expectationsC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4585","OMER","CRMD","CANC","LEGN","BK4505","MEMS","MEDI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159753","title":"Cormedix Q2 EPS $0.29 Beats $0.25 Estimate, Sales $101.931M Beat $95.621M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159753","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159753?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:34","pubTimestamp":1786620863,"startTime":"0","endTime":"0","summary":"Cormedix Q2 EPS $0.29 Beats $0.25 Estimate, Sales $101.931M Beat $95.621M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/CRMD","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cormedix.com","stockEarnings":[{"period":"1week","weight":0.0526},{"period":"1month","weight":0.0393},{"period":"3month","weight":0.0948},{"period":"6month","weight":0.0526},{"period":"1year","weight":-0.2639},{"period":"ytd","weight":-0.2949}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0088},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.1241},{"period":"ytd","weight":0.1326}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.133293},{"month":2,"riseRate":0.5,"avgChangeRate":0.066552},{"month":3,"riseRate":0.5,"avgChangeRate":0.041342},{"month":4,"riseRate":0.5,"avgChangeRate":-0.005656},{"month":5,"riseRate":0.25,"avgChangeRate":-0.108379},{"month":6,"riseRate":0.529412,"avgChangeRate":0.045878},{"month":7,"riseRate":0.411765,"avgChangeRate":0.049729},{"month":8,"riseRate":0.588235,"avgChangeRate":0.029573},{"month":9,"riseRate":0.352941,"avgChangeRate":0.021777},{"month":10,"riseRate":0.470588,"avgChangeRate":0.044291},{"month":11,"riseRate":0.4375,"avgChangeRate":0.046811},{"month":12,"riseRate":0.4375,"avgChangeRate":0.057824}],"exchange":"NASDAQ","name":"CorMedix Inc.","nameEN":"CorMedix Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CorMedix Inc.,CRMD,CorMedix Inc.股票,CorMedix Inc.股票老虎,CorMedix Inc.股票老虎国际,CorMedix Inc.行情,CorMedix Inc.股票行情,CorMedix Inc.股价,CorMedix Inc.股市,CorMedix Inc.股票价格,CorMedix Inc.股票交易,CorMedix Inc.股票购买,CorMedix Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}